WITHDRAWN: (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione attenuates bleomycin-induced pulmonary fibrosis in rats
guangcheng wang,baowen qi,liang ma,yinghua ma,hao zheng,yuquan wei,youfu luo,lijuan chen
DOI: https://doi.org/10.1016/j.biopha.2011.04.029
IF: 7.419
2011-01-01
Biomedicine & Pharmacotherapy
Abstract:Idiopathic pulmonary fibrosis is a lethal, chronic disease characterised by an excessive deposition of collagen. In a previous study, we developed a rapid screening method to evaluate the potency of chemotaxic inhibition in RAW264.7 cells stimulated with monocyte chemotactic protein-1 (MCP-1). We found that (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione (SKLB010) exhibited the most potent inhibitory effect, with an IC 50 of 0.72 μM. In the present study, we investigate the preventive effects of orally administered SKLB010 on a rat model of endotracheal bleomycin-induced lung injury and further explore the underlying mechanisms of SKLB010. Our results show that SKLB010 significantly inhibited the bleomycin-induced increase in macrophage, neutrophil and lymphocyte counts, as well as the levels of TNF-α, IL-1β, and IL-6 in the bronchoalveolar lavage fluid ( P < 0.05). Treatment with SKLB010 also decreased the augmented collagen deposition in bleomycin-exposed rats. SKLB010-treated animals showed a 34.6% reduction ( P < 0.05) in the hydroxyproline content at the 25 mg/kg dose and a 56.7% reduction ( P < 0.05) at the 50 mg/kg dose compared to the bleomycin only group. A histological assessment using a semi-quantitaive score revealed a reduction in both collagen deposition and the number of inflammatory cells in SKLB010-treated rats compared to those receiving bleomycin alone. The up-regulation of TGF-β 1 and Smad3 mRNA expression was also suppressed by SKLB010 treatment. Taken together, our findings illustrate that SKLB010 is able to effectively prevent pulmonary fibrosis by suppressing the recruitment of inflammatory cells and the production of inflammatory cytokines. Our work suggests that SKLB010 might be a novel agent for the treatment of pulmonary fibrosis. Keywords SKLB010 Bleomycin Pulmonary fibrosis Abbreviations IPF idiopathic pulmonary fibrosis BALF bronchoalveolar lavage fluid BLM bleomycin SKLB010 (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione MCP-1 monocyte chemotactic protein-1 1 Introduction Inflammatory responses have been associated with the initial stages of idiopathic pulmonary fibrosis (IPF). The prognosis of IPF is poor, with a median survival of 2–2.8 years. During the development of this disease, an excessive deposition of collagen and increased fibroblastic proliferation occurs, leading to lethal pathological changes. Thus, an effective treatment strategy for pulmonary fibrosis should be applied during the initial stage [1] , which is associated with numerous inflammatory cytokines, such as TNF-α, IL-1β, IL-6 and monocyte chemotactic protein-1 (MCP-1) [2,3] . Among these inflammatory cytokines, MCP-1 has been reported to participate in the process of stimulating IL-1β and IL-6 secretion through the regulation of TNF-α and is considered to be a major pro-inflammatory factor [4–6] . The correlation between MCP-1 and pulmonary fibrosis has also been well documented [7] . Recent reports have shown that MCP-1 is involved in the transcriptional activation of the TGF-β 1 -mediated stimulation of collagen expression [8] . TGF-β 1 is a major mediator of collagen synthesis for repairing persistent inflammation responses both in vitro and in vivo [9] . It is capable of enhancing the production and secretion of the extracellular matrix (ECM). Although this factor has low expression levels in healthy lung tissue, there is an increasing body of data suggesting that the expression of TGF-β 1 is up-regulated in the fibrotic areas of both human and animal lungs [10,11] . Smads are a family of cytoplasmic signal transducer proteins. It has been suggested that the TGF-β 1 /Smad3 pathway is the key element in the progressive nature of pulmonary fibrosis and collagen expression in mouse lungs [12–14] . One possible molecular mechanism is that Smad3 is involved in the transcriptional activation of the TGF-β 1 -mediated stimulation of collagen expression [15,16] . Smad3 is also necessary for the formation of the transcriptional activation complex in the stimulation of the expression of the type I collagen gene by TGF-β 1 ligands in human skin fibroblasts [17,18] . Bleomycin (BLM), when used as a chemoagent in the treatment of lymphoma, squamous cell carcinomas and germ cell tumours, can generate toxicity and induce an inflammation response and fibrosis in a short period time. BLM has been widely used to induce experimental lung fibrosis [19,20] . In our previous study, we established a rapid screening method for evaluating the inhibition of chemotaxis in macrophage-like RAW264.7 cells stimulated by MCP-1. We found that several analogues of thiazolidinediones (TZDS) had inhibitory effects on the chemotaxis of RAW264.7 cells. Among them, (Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione (SKLB010) exhibited the strongest inhibition, with an IC 50 of 0.72 μM [21] . Therefore, we hypothesised that SKLB010 might ameliorate BLM-induced pulmonary fibrosis. The related molecular mechanisms were also investigated. 2 Materials and methods 2.1 Reagent and animals Three- to four-week-old female Sprague-Dawley rats weighing 200 ± 30 g were purchased from the Western China Experimental Animal Center. The animals were maintained at the Sichuan University animal facility under specific, pathogen-free conditions on a 12-h light/dark cycle at a constant temperature with food and water. All experiments followed the criteria outlined in the “Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of Sciences and published by the National Institutes of Health. SKLB010 was synthesised according to our previous protocol at more than 99.5% purity. The structure and purity were confirmed with high performance liquid chromatography, a Q-TOF Premier Mass Spectrometer (Waters Micromass, Milford, USA) and nuclear magnetic resonance (Bruker Avance 400 NMR system; Fig. 1 F) . SKLB010 was dissolved in saline containing 5% (v/v) Tween-80 (Sigma-Aldrich, St. Louis, USA). 2.2 Treatment groups Rats were housed for one week and then randomly assigned to one of four experimental groups ( n = 10 for each group): A: fibrosis was induced with BLM and then treated with 25 mg/kg SKLB010 (SKLB010 [25 mg/kg] + BLM); B: fibrosis was induced with BLM and then treated with 50 mg/kg SKLB010 (SKLB010 [50 mg/kg] + BLM); C: fibrosis was induced with BLM and the animals were then given saline (vehicle + BLM); D: rats were given saline only (control). The doses of SKLB010 used were based on our previous in vivo study [21] . 2.3 Induction of pulmonary fibrosis animal model The animals were anesthetised with intraperitoneal injections of pentobarbital sodium. Pulmonary fibrosis was induced with an intratracheal injection of 0.2 mL saline containing bleomycin (5 U/kg; Nihonkayaku, Osaka, Japan). In groups A and B, SKLB010 (25 and 50 mg/kg, respectively) was orally administered via gavage, whereas rats in control and BLM groups were treated with equivalent volumes of saline on day 1. Day 0 refers to the administration of BLM. All the groups were given the same dosage once daily for 28 days. On day 14, five animals from each group were sacrificed for the bronchoalveolar lavage (BALF) assay. On day 28, the remaining five animals from each group were sacrificed for the hydroxyproline and histopathological assays. 2.4 Bronchoalveolar lavage Rats were anesthetised and sacrificed on day 14. BALF was obtained by washing the right lung three times with a total of 1.5 mL of saline through a tracheal cannula. Cell suspensions were centrifuged at 4 °C and 1200 rpm for 10 min. The supernatant was collected and stored at −80 °C for biochemical analysis. A hemocytometer and a microscope were used to count the total cells and identify the different types of cells according to the Wright-Giemsa staining method. 2.5 Hydroxyproline analysis The level of hydroxyproline is an important indicator of the collagen content in pulmonary fibrosis. To assess the effects of SKLB010 treatment on pulmonary fibrosis, frozen lung samples were obtained on day 28, as described previously. The commercial hydroxyproline detection kit (Nanjing Jiancheng Bioengineering, China) was used to examine the hydroxyproline content in lungs according to the manufacturer's instructions. The absorbance at 550 nm from each group was read on a spectrophotometer. The results are expressed as mg/g in wet lung tissue. 2.6 Elisa for cytokines assay in BALF The supernatant from the BALF collected on day 14 was stored at −80 °C until the assay. The concentrations of TNF-α and IL-1β in the BALF were analysed by Elisa using commercially available kits (R&D Biotechnology, China) and the manufacturer's instructions. 2.7 RT-PCR Total RNA was isolated using a Trizol reagent (Invitrogen, USA) according to the manufacturer's instructions. The concentration of RNA was determined, and cDNA was generated using the total RNA with a Reverse Transcriptase kit (TaKaRa, Japan). The primer sequences for the cytokine genes are as follows: • TGF-β 1 : sense 5’-CTACTACGCCAAAGAAGTCACC-3’ and antisense 5’-GAAAGCCCTGTATTCCGTCTC-3’; • Smad3: sense 5’-AAGGGCGAGCAGAACGGG-3’ and antisense 5’-GGGGATGGAATGGCTGTAG-3’; • GAPDH: sense 5’-GTGGAAGAATGGGAGTTGCTGT-3’and antisense 5’-GTGCTGAGTATGTCGTGGAGTCT-3’. PCR amplification was carried out for 30 cycles as follows: denaturation at 94 °C for 1 min, primer annealing for 1 min (the annealing temperatures were 59, 54 and 60 °C for TGF-β 1 , Smad3 and GAPDH, respectively) and extension at 72 °C for 30 s [22] . 2.8 Histopathologiacal and immunohistochemical examination of lung tissues Tissues were harvested from the sacrificed animals on day 28. The lungs from each group were fixed in 10% neutral-buffered formalin, embedded in paraffin and then stained with haematoxylin, eosin and Masson trichrome. The Ashcroft score was used to determine the extent of fibrotic changes and to indicate the severity of pulmonary inflammation. Lung sections were processed together on the same microscope slide with histopathological assessment. After rehydration, 5-mm lung sections were incubated in 0.3% (v/v) hydrogen peroxide in PBS at room temperature to quench endogenous peroxidase activity. This was followed by a 30-min incubation in 0.1% (w/v) pepsin in 0.01 NHCL at 37 °C to permeabilise the cell membranes and expose epitopes. The sections were incubated with primary antibodies diluted in 3% (v/v) normal goat serum (NGS) and 1% (w/v) BSA overnight at 4 °C. Sections were then incubated for 1 h in secondary antibody (1:200 biotinylated goat anti-rabbit IgG; Vector Laboratories, Burlington, ON) at room temperature, and incubated for 1 h with an avidinbiotin complex reagent (Vector Laboratories). Immunoperoxidase staining was developed using a diaminobenzidine peroxidase substrate kit (Vector Laboratories). 2.9 Statistical analysis of results SPSS 16.0 was used to determine the significance of differences between the control group and experimental groups. The values are expressed as mean ± SEM and analysed using a one-way analysis of variance (Anova) followed by a Tukey–Kramer multiple comparisons test. Differences were considered significant if P < 0.05. 3 Results 3.1 SKLB010 ameliorated the BLM-induced acute pneumonia disease response After 14 days of treatment with SKLB010, the number of macrophages, neutrophils and lymphocytes in the BALF were counted. As shown in Table 1 , after receiving an intratracheal administration of BLM, the total cell count and number of macrophages, neutrophils and lymphocytes in the BALF were significantly increased in vehicle + BLM group, compared with those of the control animals. In contrast, treatment with 25 mg/kg SKLB010 caused a 32.4% ( P < 0.05) reduction in the number of macrophages compared with the vehicle + BLM group, whereas the levels of neutrophils and lymphocytes decreased by 34.9% ( P < 0.05) and 36.1% ( P < 0.05), respectively. Treatment with 50 mg/kg SKLB010 caused a 51.9% ( P < 0.05) reduction in the number of macrophages compared with the vehicle + BLM group, whereas the neutrophils and lymphocytes were decreased by 65.9% ( P < 0.05) and 48.1% ( P < 0.05), respectively. 3.2 SKLB010 ameliorated the lung histopathological changes in bleomycin-induced pulmonary fibrosis. After 28 days of treatment, the rats were sacrificed, and the lungs were fixed in 10% neutral formalin to dehydrate, embedded into paraffin and cut into 3 μm thickness sections. The sections were stained using the H&E method to determine whether the BLM-induced pulmonary fibrosis was decreased by treatment with SKLB010. As shown in Fig. 1 A–D, the lungs from rats receiving BLM alone showed severe lung alveolitis and injury with marked interstitial infiltration of the inflammatory cells, extensive thickening of the interalveolar septa, increased interstitial cells and a large fibrotic area ( Fig. 1 A). The lungs of control rats had normal alveolar spaces and normal thickening of alveolar septa ( Fig. 1 D). In contrast, the lungs from rats receiving 25 and 50 mg/kg SKLB010 treatments were effectively protected, and the interalveolar inflammation and tissue damage was markedly reduced ( Fig. 1 B–C). These results were further confirmed with the Ashcroft score. The overall grades of the fibrotic changes of the lungs were scored on day 28. The score of the BLM-exposed group increased to 7.06 ± 0.15 compared with 1.55 ± 0.13 from control group (mean ± SEM, P < 0.05). In sharp contrast, treatment with either 25 or 50 mg/kg SKLB010 significantly improved the lung damage and Ashcroft scores (4.11 ± 0.29; P < 0.05 vs. BLM group and 2.95 ± 0.69; P < 0.05 vs. BLM group, respectively; Fig. 1 E). 3.3 SKLB010 ameliorated collagen accumulation and the level of hydroxyproline content in BLM-induced lung tissue Masson staining is a method for quantifying the collagen accumulation in locally defined tissue areas. As shown in Fig. 2 A–D , the lungs of rats showed severe alveolitis and injury in BLM groups as manifested with interalveolar inflammation, thickening alveolar wall, bronchial erosion, and an excessive amount of collagen deposition around the alveoli ( Fig. 2 A). On the other hand, rats receiving either 25 or 50 mg/kg SKLB010 treatments showed a marked suppression of the BLM-induced inflammatory cellular infiltration, as evidenced by decreased collagen deposition in lung tissues ( Fig. 2 B–C). The lungs of the control rats had normal alveolar spaces and normal thickening of the alveolar septa ( Fig. 2 D). The lung hydroxyproline level, a marker of collagen deposition, was significantly increased in the BLM-induced group compared with the control group ( P < 0.05; Fig. 2 E). However, treatment with SKLB010 significantly reduced the hydroxyproline content compared to the BLM-induced group, with a 34.6% reduction ( P < 0.05) for 25 mg/kg SKLB010 + BLM and a 56.7% reduction ( P < 0.05) for 50 mg/kg SKLB010 + BLM. These results show that SKLB010 is able to effectively reduce the BLM-induced collagen in lung tissue and inhibit the process of pulmonary fibrosis. 3.4 SKLB010 reduced BLM-induced inflammatory cytokines in BALF Inflammatory cytokines play important roles in the pathogenesis and development of pulmonary fibrosis. As shown in Fig. 2 F(a–c), BLM significantly increased the levels of TNF-α, IL-1β and IL-6 in BALF compared with the control group. The levels of TNF-α, IL-1β and IL-6 in BALF were increased to 195.3 ± 14.6, 173.24 ± 2.14 and 94.52 ± 5.96 pg/mL, respectively, compared with 73.85 ± 3.67, 39.8 ± 6.9 and 34.39 ± 2.51 ( P < 0.05) in the control group. SKLB010 significantly reduced the levels of TNF-α, IL-1β and IL-6 in BALF to 172.7 ± 11.2, 107.8 ± 21.6 and 69.2 ± 11.3 pg/mL in the 25 mg/kg SKLB010 + BLM group and 131.3 ± 10.7, 79.6 ± 8.8, 39.7 ± 4.2 pg/mL in the 50 mg/kg SKLB010 + BLM group ( P < 0.05), respectively. 3.5 SKLB010 down-regulated TGF-β 1 protein and mRNA expression TGF-β1 is one of a fibrogenic cytokines involved in the development of pulmonary fibrosis. Using immunohistochemistry and RT-PCR, we observed changes in the expression of TGF-β 1 . As shown in Fig. 3 A–D , TGF-β 1 -positive cells localised in the cytoplasm of pulmonary fibrotic areas were observed in the BLM-induced group ( Fig. 3 A). The degree of TGF-β 1 expression was significantly down-regulated after treatment with SKLB010 ( Fig. 3 B–C). TGF-β 1 mRNA was also quantified using RT-PCR. As shown in Fig. 3 E–F, the RT-PCR products of TGF-β 1 were separated using agarose gel electrophoresis ( Fig. 3 E), and the relative expression intensities were evaluated ( Fig. 3 F). The expression of TGF-β 1 mRNA was similar to the expression of TGF-β 1 protein. TGF-β 1 mRNA was over-expressed in the lung tissue of the vehicle + BLM group. SKLB010 significantly suppressed the over-expression of TGF-β 1 mRNA. 3.6 SKLB010 down-regulates Smad3 protein and mRNA expression To investigate whether Smad3 plays a pivotal role during tissue injury, we measured the changes in Smad3 expression using immunohistochemistry and RT-PCR. As illustrated in Fig. 4 A–D , the expression of Smad3 was higher in the BLM group, and higher amounts of Smad3-positive cells localised in cytoplasm of pulmonary fibrotic areas were observed ( Fig. 4 A) compared with the control group ( Fig. 4 D). SKLB010 administration was associated with a significant down-regulation of Smad3 expression ( Fig. 4 B–C). RT-PCR revealed that BLM up-regulated the expression of Smad3 mRNA, whereas SKLB010 significantly suppressed the over-expression of Smad3 mRNA ( Fig. 4 E–F). 4 Discussion and conclusion Our results demonstrated that SKLB010 ameliorated the BLM-induced pulmonary fibrosis. After treatment with SKLB010, the thickening of the alveolar gap and the septal damage were reduced compared with the BLM-induced group. The levels of macrophages, lymphocytes, neutrophil and the content of hydroxyproline in the treatment groups were also significantly reduced compared with the BLM-induced group ( P < 0.05). To determine the role of SKLB010 in cellular infiltration, we examined the effect of SKLB010 on the BLM-induced cellular accumulation in BALF at day 14 [23] . The cell counts and inflammatatory cytokines in the BALF were consistent with previous reports [24] . PPAR-γ is a member of the nuclear receptor family of transcription factors that mediates growth, differentiation and inflammation [25] . Natural ligands of PPAR-γ are fatty acids, arachidonic acid metabolites, and prostaglandins. The synthetic ligands of PPAR-γ include non-steroidal anti-inflammatory drugs. When a ligand binds, the PPAR-γ receptor forms a heterodimer with the retinoid X receptor and is activated. This heterodimer can interfere with mitogen-activated protein kinase and the nuclear factor-κB pro-inflammatory pathways [26,27] . Thiazolidinediones are synthetic ligands of PPARγ and have been clinically used for the treatment of non-insulin-dependent diabetes [28,29] . The anti-diabetic properties of glitazones are revealed by the fact that these compounds, by activating PPAR-γ, counter the insulin resistance-generating effects of TNF-α [30] . Unfortunately, the first thiazolidinedione, troglitazone, was taken off the market because of serious liver function failure and water-sodium retention among users. Recently, it has been suggested that PPARγ participates in the control of inflammation, especially in modulating the production of inflammatory mediators by inhibiting the activation of NF-κB. A number of studies have recently suggested that pioglitazone and rosiglitazone, two representative anti-diabetic compounds, may represent a possible novel pharmacological treatment for liver fibrosis. The mechanisms underlying the reduced liver fibrogenesis were consistent with the actions of TZDs on isolated HSC and included the reduced expression of TGF-β 1 , procollagen I, fibronectin and tissue inhibitor of metalloproteinases (TIMPs). Considerable evidence indicates that PPAR-γ agonists may have beneficial effects in other diseases as well because of their anti-inflammatory properties. PPAR-γ agonists negatively regulate pro-inflammatory cytokine production in mononuclear cells as well as adhesion molecule expression on endothelial cells [31] . SKLB010 shares the same structural backbone as thiazolidinediones. In our previous studies, we found that SKLB010 had potential anti-inflammatory activities. The underlying mechanisms revealed that suppressing acute hepatitis by SKLB010 is likely to modulate the NF-κB-related signalling pathways through the IKK/IκB-dependent pathways. Hence, we hypothesised that SKLB010 may have a preventive effect on BLM-induced pulmonary fibrosis in rats. TGF-β 1 is a regulator of ECM remodelling and the promoting factor in the pathogenesis of pulmonary fibrosis [32] . This hypothesis is supported by findings of enhanced TGF-β 1 expression in the development of fibrosis. In this study we showed that SKLB010 reduced the levels of active TGF-β 1 in the lung tissues and ultimately resulted in an impairment of fibrosis formation. These data are in line with studies in experimental hepatic fibrosis, in which glitazone treatment reduced the activation of hepatic stellate cells. Smad3 is necessary for the formation of the transcriptional activation complex in the stimulation of type I collagen gene expression by TGF-β 1 ligands in human skin fibroblasts. In this study, we found that SKLB010 administration significantly down-regulated the expression of Smad3 at both protein and mRNA levels. These results are consistent with our hypothesis that SKLB010 attenuated the BLM-induced pulmonary fibrosis by inhibiting the activation of pro-inflammatory factors and suppressing the expression of TGF-β 1 and Smad3. In addition, we also tested whether SKLB010 was capable of reducing the fibrosis area by applying late therapeutic strategies. SKLB010 was administrated at day 7 after rats were induced by BLM. The histopathological assessment demonstrated that there were no significant differences between SKLB010-treated and BLM groups. This suggests that the major effects of SKLB010 occur during the initial injury responses triggered by BLM but are not capable of decreasing the level of fibrosis after the pro-inflammatory responses have occurred. In addition, we did not observe any toxicity produced by SKLB010 in the tissues and organs of the experimental animals. In summary, we have shown that early treatment with SKLB010, a novel derivative of TZDs, can effectively prevent BLM-induced pulmonary fibrosis and lung damage in rats. The effect of SKLB010 on pulmonary fibrosis is associated with a reduced accumulation of collagen and an improved pathologic grading. SKLB010 also significantly diminished the levels of macrophage, neutrophil and lymphocytes as well as the levels of TNF-α, IL-1β and IL-6 in BALF. Although only the preventive effects were evaluated, our findings demonstrate that SKLB010 was effective for preventing pulmonary fibrosis by suppressing the recruitment of inflammatory cells and the production of inflammatory cytokines. Our data suggest that SKLB010 might be a novel agent for the treatment of pulmonary fibrosis. Disclosure of interest The authors have not supplied their declaration of conflict of interest. References [1] J.D. Allen Cooper Jr. Pulmonary fibrosis pathways are slowly coming into light Am J Respir Cell Mol Biol 22 2000 520 523 [2] L.K. Gong H.L. Xiang W. Hui Z. Ling C. Yan M.Q. Xin Feitai attenuates bleomycin-induced pulmonary fibrosis in rats Biol Pharm Bull 27 2004 634 640 [3] K. Zhang S.H. Phan Cytokines and pulmonary fibrosis J Biol Signal 5 1996 232 239 [4] Y. Jiang D.I. Beller G. Frendl D.T. Graves Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes J Immunol 148 1992 2423 2428 [5] M.A. Gavrilin M.F. Deucher F. Boeckman P.E. Kolattukudy Monocyte chemotactic protein-1 upregulates IL-1 beta expression in human monocytes Biochem Biophys Res Commun 277 2000 37 44 [6] P. Biswas F. Delfanti S. Bernasconi M. Mengozzi M. Cota N. Polentarutti Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line Blood 91 1998 258 265 [7] K. Zhang M. Gharaee-Kermani M.L. Jones J.S. Warren S.H. Phan Lung monocyte chemoattractant protein-1 gene expression in bleomycin-induced pulmonary fibrosis J Immunol 153 1994 4733 4741 [8] D.T. Graves Expression of monocyte chemoattractant protein-1 mRNA in human idiopathic pulmonary fibrosis Proc Natl Acad Sci U S A 10 1992 5371 5375 [9] M. Gharaee-Kermani E.M. Denholm S.H. Phan Costimulation of fibroblast collagen and transforming growth factor beta 1 gene expression by monocyte chemoattractant protein-1 via specific receptors J Biol Chem 271 1996 7779 7784 [10] N.I. Chaudhary A. Schnapp J.E. Park Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model Am J Respir Crit Care Med 173 2006 769 776 [11] G. Raghu S. Masta D. Meyers A.S. Narayanan Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of transforming growth factor-beta Am Rev Respir Dis 140 1989 95 100 [12] D. Warburton Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice Am J Physiol Lung Cell Mol Physiol 282 2002 585 593 [13] M. Meng Y.Q. Li M.X. Yan Effects of epigallocatechinpdlate on diethyldithiocarbamate-induced pancreatic fibrosis in rats Biol Pharm Bull 30 2007 1091 1096 [14] P. Bonniaud P.J. Margetts K. Ask K. Flanders J. Gauldie M. Kolb TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis J Immunol 175 2005 5390 5395 [15] S.J. Chen W. Yuan S. Lo M. Trojanowska J. Varga Interaction of smad3 with a proximal smad-binding element of the human alpha2(I) procollagen gene promoter required for transcriptional activation by TGF-beta J Cell Physiol 183 2000 381 392 [16] A. Mauviel SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta Proc Natl Acad Sci U S A 95 1998 14769 14774 [17] S.J. Chen W. Yuan Y. Mori A. Levenson M. Trojanowska J. Varga Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3 J Invest Dermatol 112 1999 49 57 [18] K. Miyazono TGF-b/SMAD signaling and its involvement in tumor progression Biol Pharm Bull 23 2007 1125 1130 [19] J.S. Hay Shahzeidi G. Laurent Mechanisms of bleomycin-induced lung damage Arch Toxicol 65 1991 81 94 [20] R.K. Scheule R.C. Perkins R. Hamilton Holian Bleomycin stimulation of cytokine secretion by the human alveolar macrophage Am J Physiol 262 1992 386 391 [21] Y.F. Luo L. Ma H. Zheng L.J. Chen R. Li C.M. He Discovery of (Z)-5-(4-methoxybenzylidene) thiazolidine-2, 4-dione, a readily available and orally active glitazone for the treatment of concanavalin A-induced acute liver injury of BALB/c mice J Med Chem 53 2010 273 281 [22] K. Jules-Elysee D.A. White Bleomycin-induced pulmonary toxicity Clin Chest Med 11 1990 1 20 [23] Wei X, Han J, Chen ZZ, Qi BW, Wang GC, Ma YH, et al. Biochem Biophys Res Commun 2010 ( doi:10.1016/j.bbrc.2010.05.109 ). [24] S.N. Giri D.M. Hyde J.M. Nakashima Analysis of bronchoalveolar lavage fluid from bleomycin-induced pulmonary fibrosis in hamsters Toxicol Pathol 14 1986 149 157 [25] J.F. Woessner Arch Jr. The determination of hydroxyproline in tissue and protein samples containing small proportions of this imino acid Biochem Biophys 93 1961 440 447 [26] X. Zhang H.A. Young PPAR and immune system—what do we know? Int Immunopharmacol 2 2002 1029 1044 [27] J.C. Parker Troglitazone: the discovery and development of a novel therapy for the treatment of type 2 diabetes Mellitus Adv Drug Deliv Rev 54 2002 1173 1197 [28] M. Stumvoll H.U. Haring Clinical effects and molecular mechanisms Ann Med 34 2002 217 224 [29] R.F. Grimble Inflammatory status and insulin resistance Curr Opin Clin Nutr Metab Care 5 2002 551 559 [30] C.S. Elangbam R.D. Tyler R.M. Lightfoot Peroxisome proliferator-activated receptors in atherosclerosis and inflammation—an update Toxicol Pathol 29 2001 224 231 [31] C.L. Surrenti A. Casini Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro Gastroenterology 122 2002 1924 1940 [32] G. Yao L.Z. Xu X.C. Wu L.L. Xu J.W. Yang H.M. Chen Preventive effects of salvianolic acid B on transforming growth factor-beta1-induced epithelial-to-mesenchymal transition of human kidney cells Biol Pharm Bull 32 2009 882 886